From: Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
Variable
ERα/PI3K ≤9, no. (%)
ERα/PI3K >9, no. (%)
P
ERα/Src
Low (≤ 10)
181 (69.6)
68 (44.2)
<0.001
High (> 10)
79 (30.4)
86 (55.8)